☆ 4.8 Letter

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

CANCER CELL (2022)

Get Full Text
Add to Collection

Journal

CANCER CELL
Volume 40, Issue 4, Pages 335-337

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2022.02.005

Keywords

-

Categories

Oncology Cell Biology

Funding

  1. Belgian Federal Government through Sciensano
  2. University of Liege through Credits Sectoriels de Recherche en Sciences de la Sante (FSR 2021)
  3. Research Foundation -Flanders [FWO G0G4220N]
  4. KU Leuven

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.